Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

INTRODUCTION: Microsatellite instability (MSI) testing and tumor mutational burden (TMB) are genomic biomarkers used to identify patients who are likely to benefit from immune checkpoint inhibitors. Pembrolizumab was recently approved by the Food and Drug Administration for use in TMB-high (TMB-H) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmeri, M., Mehnert, J., Silk, A.W., Jabbour, S.K., Ganesan, S., Popli, P., Riedlinger, G., Stephenson, R., de Meritens, A.B., Leiser, A., Mayer, T., Chan, N., Spencer, K., Girda, E., Malhotra, J., Chan, T., Subbiah, V., Groisberg, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717431/
https://www.ncbi.nlm.nih.gov/pubmed/34953399
http://dx.doi.org/10.1016/j.esmoop.2021.100336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717431/
https://www.ncbi.nlm.nih.gov/pubmed/34953399
http://dx.doi.org/10.1016/j.esmoop.2021.100336

Ejemplares similares